iShares Nasdaq Biotechnology ETF (IBB)

121.89 -0.46  -0.38% NASDAQ Jan 17, 20:00 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 121.83
Discount or Premium to NAV 0.05%
Turnover Ratio 18.00%
1 Year Fund Level Flows -1.694B

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 0.74% 0.69% 3.36% 90
3M 18.36% 18.22% 18.51% 42
6M 15.58% 15.46% 14.67% 37
YTD 1.15% 1.05% 2.52% 88
1Y 11.23% 11.14% 20.23% 92
3Y 10.28% 10.24% 15.66% 82
5Y 3.03% 3.02% 8.59% 91
10Y 16.07% 16.06% 14.80% 27
15Y 11.59% 11.59% 11.31% 46
20Y -- -- 9.78% --
As of Jan. 17, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.07% 0.07% 0.00%
Stock 99.93% 99.93% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Jan. 16, 2020

Region Exposure

Americas 93.20%
North America 93.20%
Latin America 0.00%
Greater Europe 5.03%
United Kingdom 1.99%
Europe Developed 2.91%
Europe Emerging 0.00%
Africa/Middle East 0.13%
Greater Asia 1.77%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.18%
Asia Emerging 1.59%
Market Classification
% Developed Markets 98.41%
% Emerging Markets 1.59%
As of Jan. 16, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.04%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 99.96%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Jan. 16, 2020

Stock Market Capitalization

Giant 9.37%
Large 35.25%
Medium 29.69%
Small 21.07%
Micro 4.61%
As of Jan. 16, 2020

Stock Style Exposure

Large Cap Value 17.03%
Large Cap Blend 18.49%
Large Cap Growth 14.78%
Mid Cap Value 1.57%
Mid Cap Blend 4.43%
Mid Cap Growth 22.75%
Small Cap Value 1.59%
Small Cap Blend 6.11%
Small Cap Growth 13.27%
As of Jan. 16, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
AMGN Amgen Inc 8.08% 241.49 +0.41%
GILD Gilead Sciences Inc 7.41% 62.98 -0.35%
VRTX Vertex Pharmaceuticals Inc 7.18% 235.83 +0.14%
BIIB Biogen Inc 6.12% 285.50 -0.22%
ILMN Illumina Inc 5.68% 324.72 -0.38%
REGN Regeneron Pharmaceuticals Inc 4.12% 385.94 +0.10%
ALXN Alexion Pharmaceuticals Inc 2.99% 113.27 +0.68%
SGEN Seattle Genetics Inc 2.22% 109.00 +1.24%
INCY Incyte Corp 2.09% 80.50 -0.15%
BMRN Biomarin Pharmaceutical Inc 1.92% 88.27 -0.96%
As of Jan. 16, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Reports
One Page Report Download

Manager Info

Name Tenure
Alan Mason 3.71 yrs
Amy Whitelaw 1.42 yrs
Greg Savage 12.01 yrs
Jennifer Hsui 7.42 yrs
Rachel Aguirre 1.42 yrs

Net Fund Flows

1M -545.61M
3M -583.22M
6M -845.81M
YTD -1.694B
1Y -1.694B
3Y -2.711B
5Y -788.62M
10Y 865.55M
As of Dec. 31, 2019

Risk Info

Beta (5Y) 1.425
Max Drawdown (All) 62.85%
Historical Sharpe Ratio (10Y) 0.8592
Historical Sortino (All) 0.472
30-Day Rolling Volatility 12.34%
Daily Value at Risk (VaR) 1% (All) 4.71%
Monthly Value at Risk (VaR) 1% (All) 19.15%

Fundamentals

Dividend Yield TTM (1-17-20) 0.17%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 20.89
Weighted Average Price to Sales Ratio 6.283
Weighted Average Price to Book Ratio 4.924
Weighted Median ROE 5.57%
Weighted Median ROA -4.03%
Forecasted Dividend Yield 0.64%
Forecasted PE Ratio 15.14
Forecasted Price to Sales Ratio 4.422
Forecasted Price to Book Ratio 3.823
Number of Holdings 220
As of Jan. 16, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 9.91%
Forecasted Book Value Growth 8.87%
Forecasted Cash Flow Growth -0.40%
Forecasted Earnings Growth 15.36%
Forecasted Revenue Growth 8.21%
As of Jan. 16, 2020

Comparables

Edit

Attributes

Key Dates
Inception Date 2/5/2001
Termination Date
Last Annual Report Date 3/31/2019
Last Prospectus Date 8/1/2019
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.